FORA Capital’s Beam Therapeutics BEAM Stock Holding History

FORA Capital’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16,122	Closed	-$2.08M	–	407
2021 Q2	$2.08M	Buy	+16,122	New	+$1.28M	0.39%	62

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's BEAM Position: Q3 2021 in Review

FORA Capital sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 16,122 shares — an estimated $2.08M sold.

FORA Capital first reported a position in BEAM in Q2 2021 and held it in 1 quarter. The position peaked at $2.08M in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

FORA Capital reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 16,122 Beam Therapeutics shares in Q3 2021, an estimated $2.08M.
FORA Capital first reported a position in Beam Therapeutics in Q2 2021 and held it in 1 quarter.
FORA Capital's Beam Therapeutics position peaked at $2.08M in Q2 2021.
231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.